Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis | PHASE1 | RECRUITING | 68 | — | — | Oct 21, 2025 | Jun 1, 2028 | Apr 14, 2026 | 3 | Georgia, Moldova +1 |
Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Plamotamab administered SC |
| Name | Type | Description |
|---|---|---|
| Plamotamab | BIOLOGICAL | Biological |
Inclusion Criteria: Adult participants with moderately to severely active RA. * Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening * Inadequate respon...